Compare AstraZeneca plc (AZN) vs Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? AstraZeneca plc trades at $158.6 (market cap $248.14B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.83. The key difference: AstraZeneca plc pays a 2.01% dividend while Roundhill Innov-100 0DTE Covered Call Strat ETF pays none, and Roundhill Innov-100 0DTE Covered Call Strat ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | QDTE | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $209.48 | $36.60 |
52-Week Low | $147.06 | $26.85 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
QDTE trades at $29.835, up 0.62% with a bearish technical signal from moving averages. The ETF faces significant concerns about its distribution strategy, with recent analysis highlighting that its high yield is funded by return of capital rather than actual earnings, leading to persistent NAV erosion. Technical indicators show resistance at $30 with support at $29, while RSI levels suggest mixed momentum signals.
The outlook remains cautious as the fund's structural issues with NAV depletion outweigh the appeal of weekly distributions. Investment opportunity exists only for those understanding the return-of-capital mechanics, while risks include continued underperformance and yield sustainability concerns in changing volatility environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →
